AstraZeneca PLC
- Open
- 162.70
- Day high
- 163.75
- Day low
- 161.95
- Prev close
- 162.70
- Volume
- 3.0M
- Mkt cap
- $251.4B
- P/E (TTM)
- 24.1
- EPS (TTM)
- $6.72
- P/B
- 5.0
- P/S
- 4.1
- Yield
- 1.98%
- Per share
- $3.21
AstraZeneca PLC (AZN) is a Healthcare company listed on NYSE. The stock is up 1% over the past year. Drillr has 1 published research article covering AZN.
AstraZeneca PLC (AZN) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
AZN earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jul 27, 2026 | $2.50 | $2.63 | +5.2% | $15.4B | -0.3% |
| Apr 29, 2026 | $2.57 | $2.58 | +0.4% | $15.3B | +2.4% |
| Nov 6, 2025 | $1.14 | $1.19 | +4.4% | $15.2B | -1.5% |
| Jul 29, 2025 | $1.09 | $1.09 | +0.0% | $14.5B | -2.1% |
| Apr 29, 2025 | $1.10 | $1.24 | +12.7% | $13.6B | -3.3% |
| Feb 6, 2025 | $1.07 | $1.05 | -1.9% | $14.9B | +11.6% |
| Jul 25, 2024 | $1.20 | $0.99 | -17.5% | $12.9B | -0.8% |
| Apr 25, 2024 | $1.22 | $1.03 | -15.4% | $12.7B | +7.7% |
| Feb 8, 2024 | $0.79 | $0.73 | -7.4% | $12.0B | -0.1% |
| Nov 9, 2023 | $0.85 | $0.87 | +2.1% | $11.5B | -0.3% |
| Jul 28, 2023 | $0.95 | $1.08 | +13.4% | $11.4B | +3.5% |
| Apr 27, 2023 | $1.07 | $0.96 | -10.5% | $10.9B | +1.2% |
AZN insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 7, 2026 | Sharma Maniofficer: SVP, Group Controller | Grant | 2 | $163.34 |
| Jul 8, 2026 | Sharma Maniofficer: See Remarks | Grant | 2 | $190.43 |
| Jun 16, 2026 | Sharma Maniofficer: See Remarks | Grant | 1 | $179.75 |
| May 22, 2026 | Sharma Maniofficer: See Remarks | Sell | 11,893 | $185.78 |
| May 8, 2026 | Sharma Maniofficer: See Remarks | Grant | 1 | $196.03 |
Source: AZN SEC Form 4 filings, latest Aug 7, 2026. For informational purposes only — not investment advice.
See the full AZN insider & 13F page →AstraZeneca PLC company profile
Overview
AstraZeneca PLC (NASDAQ:AZN) is a British-Swedish multinational biopharmaceutical company founded in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the United Kingdom. The company traces its roots back to 1992 when Zeneca was incorporated, with the current entity emerging from the strategic combination that created one of the world's largest pharmaceutical companies. Headquartered in Cambridge, United Kingdom, AstraZeneca has evolved into a global leader in prescription medicines, focusing on innovative treatments across oncology, cardiovascular, respiratory, and rare diseases. The company operates through a network of 31 manufacturing sites worldwide and maintains strategic research and development centers across multiple continents, serving healthcare providers and patients in over 100 countries.
Business
AstraZeneca operates in the global pharmaceutical industry, specifically focusing on the discovery, development, manufacturing, and commercialization of prescription medicines. The pharmaceutical industry is characterized by lengthy development cycles, substantial research investments, and strict regulatory oversight, where companies must navigate complex clinical trials and regulatory approvals before bringing medicines to market. The company's business is organized into three primary therapeutic segments. Oncology represents the largest segment, generating approximately 41% of total revenue ($22.4 billion in 2024), focusing on cancer treatments including targeted therapies and immunotherapies. Key oncology products include Tagrisso for lung cancer, Imfinzi for various cancers, Lynparza for ovarian and breast cancers, and Enhertu, an antibody-drug conjugate for HER2-positive cancers. Biopharmaceuticals accounts for roughly 40% of revenue ($21.9 billion in 2024) and encompasses two main areas: Cardiovascular, Renal & Metabolism (CVRM) medicines like Farxiga for diabetes and heart failure, Brilinta for cardiovascular protection, and Crestor for cholesterol management; and Respiratory & Immunology treatments including Symbicort and Breztri for asthma and COPD, plus newer immunology medicines like Fasenra and Tezspire. Rare Diseases comprises approximately 16% of revenue ($8.8 billion in 2024), featuring specialized treatments for uncommon conditions such as Soliris and Ultomiris for complement-mediated rare diseases, along with treatments for genetic disorders and rare metabolic conditions. This segment also includes COVID-19 related products like Vaxzevria vaccine and Beyfortus for respiratory syncytial virus prevention. The company's product portfolio spans from traditional small molecule drugs to cutting-edge biotechnology treatments including monoclonal antibodies, antibody-drug conjugates (ADCs), and emerging modalities like cell therapies and bispecific antibodies. AstraZeneca serves both primary care physicians who treat common conditions and specialist physicians in hospitals and specialized clinics who manage complex diseases.
Revenue model
AstraZeneca generates revenue primarily through direct product sales of prescription medicines to healthcare providers, distributors, and government health systems worldwide. The company employs a traditional pharmaceutical business model where it invests heavily in research and development to create new medicines, conducts extensive clinical trials to prove safety and efficacy, obtains regulatory approvals, and then commercializes these products globally. The company's customers include hospitals, specialty clinics, retail pharmacies, government health services, and insurance providers who purchase medicines for patient treatment. Revenue is also generated through collaboration agreements and licensing deals with other pharmaceutical companies, where AstraZeneca may receive upfront payments, milestone payments upon achieving development goals, and royalties on sales of partnered products. Geographic revenue distribution shows strong diversification: approximately 43% from the United States (the world's largest pharmaceutical market with premium pricing), 21% from Europe, 13% from China, and 14% from other emerging markets. This geographic spread provides both growth opportunities in developing markets and stability from established markets. Several factors significantly impact AstraZeneca's profitability margins. Patent protection is crucial - when key patents expire, generic competition can dramatically reduce both market share and pricing power, as seen with older products like Crestor. Regulatory pricing pressures are intensifying globally, particularly with the U.S. Medicare Part D redesign and Inflation Reduction Act allowing government price negotiations for certain drugs. Currency fluctuations affect international revenue when converted to reporting currency. Manufacturing efficiency and scale economics become increasingly important as the company expands its global production network. Pipeline success rates directly impact long-term profitability, as successful new drug launches can generate billions in peak annual sales, while failed late-stage trials represent substantial sunk costs. Competition from biosimilars and innovative competitors pressures both market share and pricing, particularly in oncology where multiple companies compete with similar mechanisms of action.
Competitive moat
AstraZeneca possesses a moderate to strong competitive moat built on several key advantages, though the pharmaceutical industry's inherent challenges limit the durability of any single competitive advantage. The company's primary moat stems from its extensive patent portfolio protecting key medicines, providing temporary monopolies that can last 10-20 years from initial filing. However, this protection is inherently time-limited, creating "patent cliffs" when exclusivity expires. The company's robust research and development capabilities represent a significant competitive advantage, with over 90 late-stage clinical trials in progress and a track record of successfully developing complex medicines across multiple therapeutic areas. AstraZeneca's expertise in emerging technologies like antibody-drug conjugates, bispecific antibodies, and cell therapies positions it well for next-generation treatments. The company's global regulatory expertise and established relationships with regulatory agencies worldwide enable faster approval processes and market access. Scale advantages in manufacturing, distribution, and marketing provide cost efficiencies and global reach that smaller competitors cannot match. The company's established relationships with healthcare providers, payers, and distributors create switching costs and preferred access. AstraZeneca's diversified therapeutic portfolio reduces dependence on any single product and provides cross-selling opportunities. However, the moat faces significant challenges. Intense competition from other large pharmaceutical companies with similar capabilities means that competitive advantages are often temporary. Regulatory pressures and government price controls increasingly limit pricing power. Biosimilar competition erodes exclusivity for biologic medicines faster than traditional generics. Patent cliffs remain inevitable, requiring constant innovation to replace declining products. The high cost and lengthy timeline of drug development, combined with high failure rates, means that maintaining competitive position requires sustained, substantial investment with uncertain returns. Additionally, emerging biotechnology companies with novel platforms and venture capital backing can potentially disrupt established players with breakthrough technologies.
Risks & safety
AstraZeneca demonstrates a strong financial position with adequate margin of safety, though some metrics warrant monitoring given the capital-intensive nature of pharmaceutical development. • Liquidity and Solvency: Cash and short-term investments of $5.5 billion provide reasonable liquidity buffer. Current ratio of 0.93 indicates tight working capital management but adequate short-term liquidity. Debt-to-equity ratio of 0.74 represents moderate leverage levels that are manageable for a large pharmaceutical company with stable cash flows. • Cash Generation: Strong operational cash flow of $11.9 billion annually and free cash flow of $7.3 billion demonstrate robust cash generation capabilities. The company is not experiencing cash burn and generates substantial excess cash for reinvestment and shareholder returns. • Valuation Metrics: Current P/E ratio of 57.7x appears elevated relative to earnings, though this reflects recent patent cliff impacts and heavy R&D investment phase. EV/EBITDA of 14.8x is more reasonable for a growing pharmaceutical company. Price-to-book ratio of 10.0x reflects significant intangible asset value in drug portfolios and pipeline. • Other Considerations: Strong revenue growth trajectory with 18% annual growth provides earnings expansion potential. Diversified geographic and therapeutic exposure reduces concentration risk. However, regulatory pricing pressures and patent expirations create ongoing headwinds requiring constant pipeline replenishment.
Recent development
Over the past several years, AstraZeneca has undergone significant strategic transformation focused on pipeline expansion and technological advancement. The company has systematically invested in next-generation drug development platforms, particularly antibody-drug conjugates (ADCs), bispecific antibodies, cell therapies, and T-cell engagers, positioning itself at the forefront of innovative cancer treatment modalities. A major strategic initiative has been the $3.5 billion investment in U.S. manufacturing and R&D capabilities, including the establishment of a sixth strategic R&D center in Beijing, demonstrating commitment to both domestic production and global innovation networks. The company has also expanded its manufacturing footprint to 31 sites globally, enhancing supply chain resilience and reducing potential tariff impacts. Aggressive business development activities have accelerated pipeline growth, including the recent acquisition of EsoBiotec for cell therapy platforms and multiple collaboration agreements with companies like Neurimmune AG, BenevolentAI, and Absci Corporation for AI-driven drug discovery. These partnerships reflect AstraZeneca's strategy to leverage external innovation while maintaining internal R&D excellence. The company has made substantial progress toward its ambitious goal of delivering at least 20 new medicines by 2030, having already launched 9 new treatments. Key recent approvals include multiple new indications for existing medicines like Imfinzi in endometrial and gastric cancers, and breakthrough therapy designations for pipeline assets. The company has also demonstrated strong execution in emerging markets, particularly with continued growth in China despite regulatory investigations, and expansion across other developing markets. Weight management and metabolic disease represents a new strategic focus area, with AstraZeneca developing oral GLP-1 treatments and combination therapies to address the large and growing obesity market, targeting both higher BMI obesity patients and lower BMI weight management populations.
AZN company profile · for informational purposes only — not investment advice.
Track AZN with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free